These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12563660)

  • 1. Deadweight loss of bacterial resistance due to overtreatment.
    Elbasha EH
    Health Econ; 2003 Feb; 12(2):125-38. PubMed ID: 12563660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward allocative efficiency in the prescription drug industry.
    Guell RC; Fischbaum M
    Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and welfare implications of parallel imports in the pharmaceutical industry.
    Jelovac I; Bordoy C
    Int J Health Care Finance Econ; 2005 Mar; 5(1):5-21. PubMed ID: 15714261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating welfare losses in the health care market.
    Peele PB
    J Health Econ; 1993 Jul; 12(2):205-8. PubMed ID: 10127779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Battle of the bugs: fighting antibiotic resistance.
    Bren L
    FDA Consum; 2002; 36(4):28-34. PubMed ID: 12184301
    [No Abstract]   [Full Text] [Related]  

  • 6. An alternative framework for evaluating welfare losses in the health care market.
    Rice T
    J Health Econ; 1992 May; 11(1):86-92. PubMed ID: 10119758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The introduction of antibiotics in 1940's revolutionized the practice of medicine.
    Kabra SK; Singhal T; Verma IC
    Indian J Pediatr; 2001 Jul; 68 Suppl 3():S5-7. PubMed ID: 11980460
    [No Abstract]   [Full Text] [Related]  

  • 8. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
    Shih YC; Prasad M; Luce BR
    Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of poverty in antimicrobial resistance.
    Planta MB
    J Am Board Fam Med; 2007; 20(6):533-9. PubMed ID: 17954860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J; Fernandes AW; Nelson W
    Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small area variations and welfare loss in the use of outpatient antibiotics.
    Filippini M; Masiero G; Moschetti K
    Health Econ Policy Law; 2009 Jan; 4(Pt 1):55-77. PubMed ID: 19099617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic resistance: the perfect storm.
    Gould IM
    Int J Antimicrob Agents; 2009 Aug; 34 Suppl 3():S2-5. PubMed ID: 19596110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists.
    Ozkurt Z; Erol S; Kadanali A; Ertek M; Ozden K; Tasyaran MA
    Jpn J Infect Dis; 2005 Dec; 58(6):338-43. PubMed ID: 16377863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment: the economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare?
    Rosenthal M
    J Health Serv Res Policy; 2004 Jan; 9(1):39-42; discussion 41-2. PubMed ID: 15006239
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective survey of antibiotic utilization in pediatric hospitalized patients to identify targets for improvement of prescription.
    Potocki M; Goette J; Szucs TD; Nadal D
    Infection; 2003 Dec; 31(6):398-403. PubMed ID: 14735382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance-induced antibiotic substitution.
    Howard DH
    Health Econ; 2004 Jun; 13(6):585-95. PubMed ID: 15185388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of demand for effective care.
    Keeler EB
    J Health Econ; 1995 Jun; 14(2):231-8; discussion 239-42. PubMed ID: 10154659
    [No Abstract]   [Full Text] [Related]  

  • 19. Patents, innovation, and the welfare effects of Medicare Part D.
    Gailey A; Lakdawalla D; Sood N
    Adv Health Econ Health Serv Res; 2010; 22():317-44. PubMed ID: 20575239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal regulations vs. political will: why human zoonotic infections increase despite precautionary bans on animal antibiotics.
    Cox LA; Ricci PF
    Environ Int; 2008 May; 34(4):459-75. PubMed ID: 18201762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.